Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837863 | 0.86 | GAA (0.36) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL9319322 | 0.85 | ALDH1A1 (0.40) | ALDH1A1GAATDP1 | |
| SCHEMBL9067391 | 0.84 | VCAM1 (0.46) | KDM4EALDH1A1GAAHSD17B10TSHR | |
| SCHEMBL29140996 | 0.83 | DGKA (0.47) | ALDH1A1GAA | |
| SCHEMBL29140984 | 0.83 | DGKA (0.47) | ALDH1A1GAA | |
| SCHEMBL25306694 | 0.83 | DGKA (0.47) | ALDH1A1GAA | |
| SCHEMBL29140974 | 0.83 | DGKA (0.47) | ALDH1A1GAA | |
| SCHEMBL29140958 | 0.83 | DGKA (0.47) | ALDH1A1GAA | |
| SCHEMBL27872791 | 0.83 | CYP4F2 (0.50) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL2431502 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1GAAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0284879-A2 | Method of inhibiting interleukin-1 release | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-10-05 | — | — | EP | claimed |
| EP-1932544-B1 | Compositions for treating a connective tissue of a mammalian host | UNIV PITTSBURGH (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-1932544-A1 | Gene transfer for treating a connective tissue of a mammalian host | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-7037492-B2 | Gene transfer for studying and treating a connective tissue of a mammalian host | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20030220283-A1 | Gene transfer for treating a connective tissue of a mammalian host | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-20020098168-A1 | Gene transfer for studying and treating a connective tissue of a mammalian host | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-07-25 | — | — | US | disclosed |
| US-6413511-B1 | INSERTION POLYPEPTIDES IN MAMMALS JOINTS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-07-02 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| EP-1171163-A1 | COMPOSITIONS CONTAINING TETRACYCLINES FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS | Antibody Systems, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-0563239-A1 | A TRUNCATED INTERLEUKIN-1 RECEPTOR GENE FOR THE TREATMENT OF ARTHRITIS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011359-A1 | A TRUNCATED INTERLEUKIN-1 RECEPTOR GENE FOR THE TREATMENT OF ARTHRITIS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1992-07-09 | — | — | WO | disclosed |
| US-5034412-A | Antiinflammatory agents, skin disorders, antidiabetic agents or antiatherosclerosis agents | MERRELL DOW PHARMACUETICALS INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-5034412-A | Antiinflammatory agents, skin disorders, antidiabetic agents or antiatherosclerosis agents | MERRELL DOW PHARMACUETICALS INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-5011857-A | Administering 2,4-di-isobutyl-6-(n,n-dimethylaminomethyl)-phenol; antiinflammatory agent, alleviating psoriasis, diabetes, atheroschlerosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-30 | — | — | US | disclosed |
| US-5011857-A | Administering 2,4-di-isobutyl-6-(n,n-dimethylaminomethyl)-phenol; antiinflammatory agent, alleviating psoriasis, diabetes, atheroschlerosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0284879-A3 | METHOD OF INHIBITING INTERLEUKIN-1 RELEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4870101-A | TETRAETHYLTHIURAM DISULFIDE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-26 | — | — | US | disclosed |
| US-4870101-A | TETRAETHYLTHIURAM DISULFIDE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0284879-A2 | Method of inhibiting interleukin-1 release | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | KDM4E 4134/4885ALDH1A1 3850/4885GAA 4525/4885 |
| US-20030092684-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | CCL11, SSB, TNF | KDM4E 3144/4885ALDH1A1 4340/4885GAA 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.